0QSS
Sign in
ERYTECH Pharma S.A.
Save
17.62M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Medical - Pharmaceuticals
Industry
ERYTECH Pharma S. A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
Similar securities
Based on sector and market capitalization
Report issue